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Malaria remains the most devastating infectious parasitic disease, 
inflicting both death and economic loses on at least half the world 
population.  Numerous attempts have been made to control the disease 
by using vector control measures or/and chemoprophylaxis, but they 
have had limited success.  Immunoprophylaxis hold promises but 
effective vaccines are still not available.  Presently, the most effective way 
of dealing with malaria is the administration of chemotherapeutic agents. 
Although drugs treatments of malaria are currently the best means of 
disease management, there is an urgent need for the development of 
effective anti-malarial drugs.   
 
Earlier assessment of Goniothalamus scortechinii King showed to possess 
significant anti-malarial properties, in vitro.  A phytochemical study of G. 
schortechinii King was thus carried out and has led to the isolation and 
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characterization of two compounds, goniothalamin and pinocembrine, 
from the bioactive chloroform fraction.  Both compounds were assayed 
for anti-malarial activity using the pLDH method.   Both exhibited anti-
malarial activity against P. falciparum in different degrees, goniothalamin 
gave an IC50 value of 4.0824 µg/ml while pinocembrine gave 19.308 
µg/ml. 
 
Goniothalamin was evaluated for its anti-malaria activity in-vivo using 4-
Day Suppressive Test against Plasmodium berghei ANKA strain in Swiss 
Albino Mice.  The 4DT was carried out by inoculating the clean mice with 
P berghei ANKA strain and the infected mice were then treated orally and 
subcutaneously with goniothalamin.  The suppression of parasite 
parasitemia and the ED90 value of goniothalamin were determined.  
Control drug used in this study was Chloroquine.  Results showed that 
goniothalamin when given orally at a dose of 90 and 120 mg/kg mice 
body weight, exhibited suppressions of P. berghei infection of 98% and 
99.7%, respectively.   Meanwhile, goniothalamin given subcutaneously at 
a dose 120 mg/kg mice body weight gave 90.5% suppression of P. berghei 
infection.  
Ex vivo assay was carried out to investigate the effect of goniothalamin 
towards P. falciparum in vitro using the mouse serum treated with 
goniothalamin.  This was done to prove that goniothalamin reaction 
toward P. falciparum should same as reaction towards P. berghei in in vivo 
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reaction.   Ex vivo test was carried out using pLDH assay with serum of 
mice given goniothalamin orally and subcutaneously.  A graph to 
determine the 90% inhibition of drugs-serum towards P. falciparum was 
plotted for each treated mice serum.  Results showed the IS90 of mice 
serum given goniothalamin orally was ranging from 0.050 to 4.00 µg/ml, 
for subcutaneous route the IS90 was ranging from 0.009-4.750 µg/ml.  A 
graph for estimating the length of time goniothalamin can remain in the 
blood was plotted.  This gave the estimated time of goniothalamin both 
given orally and subcutaneously can remained a minimum of 6 hours in 
the blood.  
 
In conclusion, goniothalamin does strongly inhibit P. falciparum, although 
it is not as potent as the standard drugs in use.  More investigations such 
as drug combination, cytotoxicity, mechanism of action and toxicology 
studies, need to be carried out in order to determine its full potential as an 
anti-malarial. 
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Malaria masih merupakan masalah  penyakit parasit berjangkit yang 
mengakibatkan kematian dan kerugian ekonomi sekurang-kurangnya  
kepada sesetengah daripada populasi dunia.   Pelbagai tindakan telah 
dijalankan untuk mengawal penyakit ini dengan menggunakan   
pengawalan vektor penyakit  atau/dan kemoprofilaksis, tetapi 
keberkesanannya adalah terbatas.  Harapan tertumpu kepada 
Immunoprofilaksis tetapi vaksin yang berkesan masih belum didapati.   
Dewasa ini teknik yang paling berkesan dalam menangani malaria adalah 
penggunaan agen kemoterapeutik.  Walaupun sekarang ini dadah untuk 
merawat malaria masih berkesan dalam pengurusan penyakit ini, tetapi 
ubat anti-malaria yang efektif masih perlu dibangunkan.   
 
Penyelidikan fitoubatan secara in-vitro ke atas pokok Goniothalamus 
scortechinii King telah manunjukan bahawa ia mempunyai khasiat sebagai 
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anti-malaria.  Penyelidikan keatas fraksi kloroform  yang bioaktif ini telah 
membawa kepada penemuan dan pengkelasan kompaun goniothalamin 
dan pinocembrine.  Assai pLDH telah dijalankan ke atas kedua-dua 
kompaun ini bagi mengesan aktiviti anti-malaria, yang mana kedua-
duanya telah menunjukkan  darjah keupayaan yang berbeza sebagai anti-
malaria apabila diuji secara in-vitro ke atas parasit P. falciparum.  Nilai IC50 
untuk goniothalamin adalah 4.0824 µg/ml dan pinocembrine sebanyak 
19.308 µg/ml.  
 
Pengujian keatas aktiviti goniothalamin  sebagai ubat anti-malaria secara 
in vivo telah dijalankan dengan kaedah “4 Day Suppressive Test” 
terhadap P. berghei strain ANKA di dalam mencit Swiss Albino.  
Khlorokuin telah digunakan sebagai kawalan dalam kajian ini.   
Keputusan telah menunjukkan bahawa pada dos 90 mg/kg dan 120 
mg/kg yang diberikan secara oral, goniothalamin telah  menindas  
peningkatan parasitemia parasit masing-masing sebanyak 98% dan 
99.7%.  goniothalamin apabila diberikan secara ‘subcutaneous’,  telah 
menindas peningkatan parasitemia parasit sebanyak 90.5%  apabila 
diberikan dos 120 mg/kg.    
 
Kajian ex vivo pula dijalankan bagi melihat keberkesanan goniothalamin 
terhadap parasit P. falciparum secara in-vitro dengan menggunakan serum 
mencit yang telah diberikan goniothalamin.  Ujian ini dijalankan bagi 
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membuktikan bahawa tindakbalas goniothalamin terhadap P. falciparum 
secara in vitro ini adalah sama kesannya apabila dijalankan secara in vivo. 
Goniothalamin telah diberikan secara oral dan ‘subcutaneous’, dan assai 
pLDH digunakan untuk menentukan 90% penyekatan  serum-dadah 
terhadap peningkatan parasitemia P. falciparum.  Graf  untuk menentukur 
90% penyekatan diplotkan bagi melihat tindakkan serum dadah ini 
terhadap P. falciparum.  Keputusan menunjukan IS90 goniothalamin 
apabila diberikan goniothalamin secara oral telah menyekat peningkatan 
parasitemia pada kepekatan yang berbeza bermula daripada julat 
kepekatan 0.050 hingga 4.00 µg/ml, manakala untuk ‘subcutaneous’ IS90 
berjulat daripada 0.009- 4.750 µg/ml.  Graf untuk melihat berapa lama 
serum-dadah boleh bertahan didalam dadah turut plotkan.  Minimum 
masa untuk serum-dadah bertahan didalam darah  dianggarkan selama 6 
jam. 
 
Kesimpulannya, goniothalamin telah menunjukan keupayaannya untuk 
menyekat P. falciparum walaupun keupayaannya tidak sekuat standard 
dadah yang digunakan.  Kajian lanjut perlu dilakukan seperti kombinasi 
dengan dadah lain, sitotoksisiti, mekanisma tindakan, kajian keracunan 
(toxicology) demi menentukan keupayaan sebenarnya sebagai agen anti-
malarial. 
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CHAPTER I 
INTRODUCTION 
 
 
Malaria 
 
Malaria continues to exact a substantial toll of human life and 
sufferings, particularly in the tropic and sub-tropic regions of the 
world.   Human malaria has been recognized since the earliest period 
of man’s recorded history, and the discovery of mosquitoes trapped in 
amber suggests its prevalence in pre-historic times. A variety of names 
have been used to describe the disease such as the shakes, March, 
Roman, jungle, intermittent fever and ague chills.  It was earlier 
thought that there was an etiological relationship between swamps 
and this fever.  The name malaria is a misnomer and has originated 
from the Italian words mala (bad) and aryia (air) since in earlier days it 
was believed to be caused by breathing bad air (Ichpujani and Bathia, 
1998 and Smyth, 1976).  
 
Malaria is caused by single celled protozoa of the genus Plasmodium.  
Plasmodium does not only infect man but also apes, monkeys, birds 
and other vertebrate hosts.  Four species of Plasmodium pathogenic to 
man are P. falciparum (malignant tertian or falciparum malaria), P. vivax 
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(benign tertian or vivax malaria, 48 hours cycles), P. malariae (quartant 
malaria, 72 hours cycles) and P. ovale (mild tertian or mild malaria).  
Species parasitic to birds are P. gallinaceum (chicken), P. elongatum, P. 
reticulum and P. cathemerium.  Simian malaria includes P. knowlesi, P. 
cynomolgi, P. inui, P. simium and P. lophure, while species parasitic to 
murine rodents are P. bergei, P. vinckei, P. chabaudi and  P. yoelii  
(Ichpujani and Bathia, 1998; LaPage, 1963; Rosenthal, 2001). 
 
 
Epidemiology 
 
In 1955, WHO launched a program to eradicate malaria.  This effort 
produced some important successes, but, for the most part, it has been 
a major disappointment.  Indeed, over recent decades, morbidity and 
mortality caused by malaria have increased in many parts of the world 
with a large proportion of the world’s population remaining at risk of 
contracting this disease (Fig. 1.1).  Hundred of millions of clinical 
episodes of malaria occur each year and it was estimated that 1.5-2.7 
million deaths resulted from these infections.  Numerous factors 
contribute to the persistence of the malaria problem and annually 
these include, among others:- 
 2
• efforts to control mosquito vectors, which were quite 
successful in some areas many years ago, have been limited by 
financial constraints and insecticide resistance 
• programs to treat and control malaria, especially in highly 
vulnerable young children and pregnant women, are limited 
by poverty in most endemic regions  
• despite many efforts, an effective malaria vaccine is not yet 
available and is unlikely to be available to those most at need 
in the near future  
• malarial parasites have consistently demonstrated the ability to 
develop resistance to available drugs 
• although great progress have been made in our understanding 
of malaria in recent years, our ability to develop new strategies 
to control the disease remain significantly limited by an 
incomplete understanding of the biology of the parasite and of 
the host’s response to parasite infection (Rosenthal, 2001)   
 
Malaysia is no exception from the risk of malaria.  Up to the days of 
the Malacca Sultanate, settlements had to be largely restricted to river 
mouths to avoid risks of malarial infections, thus curtailing population 
growth.  In 1829, forty years after Penang Island was first occupied, 
one third of the deaths were caused by malaria (Lim, 2001).   
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Table 1.1 shows the number of malarial cases reported in 2001 and 
2002 according to the infecting species in Malaysia.   In 2001, P. 
falciparum and P. vivax account for just below 50% of malarial cases but 
in 2002, the cases increased to more than 50% for P. falciparum and 50% 
for P. vivax. In Sabah, malarial cases for 2001 were 54.87% and this 
increased to 64.2% in 2002.  Malarial cases in Sarawak in 2001 and 2002 
remained under 20% (MOH Annual  Report, 2002).  
 
 
Figure 1.1:  Regions of the world at risk of malarial infections. 
(The shrinking range of malaria is depicted by overlaying WHO maps 
for malaria risk for the year 1946 (yellow), 1966 (brown) and 1994 
(red).  
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